Last reviewed · How we verify
Methoxsalen+ECP
Methoxsalen combined with extracorporeal photochemotherapy (ECP) uses a photosensitizing agent activated by ultraviolet A light to induce apoptosis in circulating malignant T cells.
Methoxsalen combined with extracorporeal photopheresis (ECP) uses a photosensitizing agent activated by ultraviolet A light to induce apoptosis in circulating malignant T cells. Used for Cutaneous T-cell lymphoma (mycosis fungoides), Peripheral T-cell lymphoma.
At a glance
| Generic name | Methoxsalen+ECP |
|---|---|
| Also known as | Uvadex |
| Sponsor | M.D. Anderson Cancer Center |
| Drug class | Photochemotherapy agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Methoxsalen is a psoralen that becomes activated when exposed to UVA light, generating reactive oxygen species that damage DNA and trigger cell death. In ECP, patient blood is treated extracorporeally with methoxsalen and UVA exposure, then reinfused, allowing selective destruction of pathogenic T cells while modulating immune responses. This combination is used primarily in cutaneous T-cell lymphomas where circulating malignant cells can be targeted.
Approved indications
- Cutaneous T-cell lymphoma (mycosis fungoides)
- Sézary syndrome
Common side effects
- Photosensitivity
- Nausea
- Pruritus
- Erythema
- Headache
Key clinical trials
- Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation. (NA)
- Extracorporeal Photopheresis in Sezary Syndrome
- EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis (PHASE2)
- Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis (NA)
- Photopheresis in Early-stage Mycosis Fungoides (PHASE2)
- Photopheresis in GvHD After Hematopoietic Transplantation: Characteristics of the Procedure and of the Cell Product
- Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts (PHASE3)
- Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methoxsalen+ECP CI brief — competitive landscape report
- Methoxsalen+ECP updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI